XORTX Adds Late Stage Gout Program to Pipeline
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...
Financial Post12d
XORTX Adds Late Stage Gout Program to Pipeline
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing We apologize, but this video has failed to load. Try refreshing ...
Mena FN11d
XORTX Adds Late Stage Gout Program To Pipeline
(MENAFN- GlobeNewsWire - Nasdaq) XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing With the clinical ...
manilatimes12d
XORTX Adds Late Stage Gout Program to Pipeline
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...
Xortx Therapeutics announces launch of late stage program to treat gout
XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...
Business Insider11d
XORTX Adds Late Stage Gout Program to Pipeline
The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLO TM 1 having advanced ...
Medscape2d
Successful Treatment With Rasburicase of a Tophaceous Gout in a Patient Allergic to Allopurinol
Diagnosis Tophaceous gout associated with urate nephropathy in a patient intolerant to allopurinol. Management Acute polyarthritis was successfully managed by intravenous bolus methylprednisolone ...
Medscape7d
Febuxostat for Treatment of Chronic Gout
Febuxostat is generally well tolerated but is significantly more expensive than allopurinol. Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to ...